Title
The molecular basis of retinal ganglion cell death in glaucoma
Date Issued
01 March 2012
Access level
metadata only access
Resource Type
review
Author(s)
Université de Montréal
Abstract
Glaucoma is a group of diseases characterized by progressive optic nerve degeneration that results in visual field loss and irreversible blindness. A crucial element in the pathophysiology of all forms of glaucoma is the death of retinal ganglion cells (RGCs), a population of CNS neurons with their soma in the inner retina and axons in the optic nerve. Strategies that delay or halt RGC loss have been recognized as potentially beneficial to preserve vision in glaucoma; however, the success of these approaches depends on an in-depth understanding of the mechanisms that lead to RGC dysfunction and death. In recent years, there has been an exponential increase in valuable information regarding the molecular basis of RGC death stemming from animal models of acute and chronic optic nerve injury as well as experimental glaucoma. The emerging landscape is complex and points at a variety of molecular signals - acting alone or in cooperation - to promote RGC death. These include: axonal transport failure, neurotrophic factor deprivation, toxic pro-neurotrophins, activation of intrinsic and extrinsic apoptotic signals, mitochondrial dysfunction, excitotoxic damage, oxidative stress, misbehaving reactive glia and loss of synaptic connectivity. Collectively, this body of work has considerably updated and expanded our view of how RGCs might die in glaucoma and has revealed novel, potential targets for neuroprotection. © 2011.
Start page
152
End page
181
Volume
31
Issue
2
Language
English
OCDE Knowledge area
Oftalmología
Medicina general, Medicina interna
Scopus EID
2-s2.0-84857108227
PubMed ID
Source
Progress in Retinal and Eye Research
ISSN of the container
13509462
Sponsor(s)
We thank Dr. Timothy E. Kennedy for helpful discussion on the manuscript and Mr. James Correia for the preparation of the figures. This work was supported by grants to A.D.P. from the Canadian Institutes of Health Research (CIHR) and the Natural Sciences and Engineering Research Council of Canada (NSERC) . A.D.P. is a Chercheur-Boursier Senior of the Fonds de recherche en santé du Québec (FRSQ).
Sources of information:
Directorio de Producción Científica
Scopus